BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.38
+0.08 (0.86%)
At close: Aug 7, 2026, 4:00 PM EDT
9.42
+0.04 (0.43%)
After-hours: Aug 7, 2026, 7:51 PM EDT
BioCryst Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 154.97 | 89.74 | 104.71 | 110.64 | 304.77 | 504.39 |
Short-Term Investments | 197.6 | 185.01 | 216.14 | 278.34 | 119.54 | 3.21 |
Cash & Short-Term Investments | 352.57 | 274.75 | 320.85 | 388.99 | 424.31 | 507.6 |
Cash Growth | 35.59% | -14.37% | -17.52% | -8.33% | -16.41% | 68.99% |
Accounts Receivable | 110.76 | 106.82 | 79.07 | 56.95 | 50.6 | 29.41 |
Inventory | 6.06 | 5.4 | 8.09 | 28.68 | 27.53 | 15.79 |
Other Current Assets | 15.3 | 17.38 | 13.96 | 21.35 | 14.06 | 13.33 |
Total Current Assets | 484.68 | 404.35 | 421.97 | 495.97 | 516.5 | 566.14 |
Net Property, Plant & Equipment | 21.67 | 18.99 | 19.79 | 20.91 | 8.62 | 8.71 |
Long-Term Investments | - | 61.16 | 20.32 | - | 18.08 | 6.83 |
Other Long-Term Assets | 51.5 | 29.66 | 28.34 | 0.08 | 6.81 | 6.47 |
Total Assets | 557.85 | 514.16 | 490.42 | 516.96 | 550 | 588.15 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 11.46 | 15.83 | 11.64 | 20.89 | 14.36 | 27.81 |
Accrued Expenses | 121.9 | 126.41 | 113.29 | 102.88 | 87.57 | 72.67 |
Short-Term Debt | 43.81 | 38.46 | 32.68 | 23.57 | - | - |
Current Portion of Leases | 15.32 | 1.63 | 2.77 | 2.65 | 3.59 | 3.24 |
Unearned Revenue | 12.32 | - | - | - | 1.22 | 1.42 |
Other Current Liabilities | 16.36 | 13.74 | - | - | - | - |
Total Current Liabilities | 208.85 | 196.07 | 160.38 | 149.99 | 105.51 | 103.72 |
Long-Term Debt | 778.38 | 427.23 | 795.92 | 811.27 | 733.28 | 585.46 |
Long-Term Leases | 11.45 | 10.01 | 10.05 | 11.24 | 5.8 | 5.96 |
Other Long-Term Liabilities | 13.46 | - | - | - | - | - |
Total Long-Term Liabilities | 803.29 | 437.25 | 805.97 | 822.5 | 739.08 | 591.42 |
Total Liabilities | 1,012 | 633.31 | 966.35 | 972.49 | 844.6 | 695.14 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2.55 | 2.13 | 2.09 | 2.06 | 1.88 | 1.84 |
Additional Paid-in Capital | 1,693 | 1,385 | 1,291 | 1,222 | 1,158 | 1,098 |
Accumulated Other Comprehensive Income | -0.53 | 0.04 | 0.92 | 1.34 | 0.03 | 0.18 |
Retained Earnings | -2,150 | -1,506 | -1,770 | -1,681 | -1,455 | -1,208 |
Shareholders' Equity | -454.29 | -119.15 | -475.93 | -455.53 | -294.6 | -106.99 |
Total Liabilities & Equity | 557.85 | 514.16 | 490.42 | 516.96 | 550 | 588.15 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 848.97 | 477.33 | 841.42 | 848.71 | 742.68 | 594.66 |
Net Cash (Debt) | -496.39 | -202.58 | -520.57 | -459.73 | -318.37 | -87.06 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -2.10 | -0.93 | -2.52 | -2.39 | -1.71 | -0.49 |
Book Value | -454.29 | -119.15 | -475.93 | -455.53 | -294.6 | -106.99 |
Book Value Per Share | -1.92 | -0.55 | -2.30 | -2.37 | -1.58 | -0.60 |
Tangible Book Value | -454.29 | -119.15 | -475.93 | -455.53 | -294.6 | -106.99 |
Tangible Book Value Per Share | -1.92 | -0.55 | -2.30 | -2.37 | -1.58 | -0.60 |